Technical Analysis for ADMA - ADMA Biologics Inc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 11.55 | 3.31% | 0.37 |
ADMA closed up 3.31 percent on Monday, July 1, 2024, on 89 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | 3.31% | |
Pocket Pivot | Bullish Swing Setup | 3.31% | |
Volume Surge | Other | 3.31% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 9 hours ago |
Upper Bollinger Band Resistance | about 10 hours ago |
Up 3% | about 10 hours ago |
Up 2% | about 10 hours ago |
Up 1 ATR | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Biology Immunology Immune System Infectious Diseases Antibodies Antibody Glycoproteins Polyclonal Antibodies
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Biology Immunology Immune System Infectious Diseases Antibodies Antibody Glycoproteins Polyclonal Antibodies
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.645 |
52 Week Low | 3.06 |
Average Volume | 3,141,300 |
200-Day Moving Average | 5.75 |
50-Day Moving Average | 9.06 |
20-Day Moving Average | 10.70 |
10-Day Moving Average | 10.93 |
Average True Range | 0.33 |
RSI (14) | 80.28 |
ADX | 47.35 |
+DI | 40.15 |
-DI | 16.21 |
Chandelier Exit (Long, 3 ATRs) | 10.65 |
Chandelier Exit (Short, 3 ATRs) | 10.40 |
Upper Bollinger Bands | 11.44 |
Lower Bollinger Band | 9.95 |
Percent B (%b) | 1.07 |
BandWidth | 13.92 |
MACD Line | 0.58 |
MACD Signal Line | 0.61 |
MACD Histogram | -0.0342 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.20 | ||||
Resistance 3 (R3) | 12.16 | 11.90 | 12.09 | ||
Resistance 2 (R2) | 11.90 | 11.74 | 11.92 | 12.06 | |
Resistance 1 (R1) | 11.73 | 11.63 | 11.82 | 11.77 | 12.02 |
Pivot Point | 11.47 | 11.47 | 11.51 | 11.49 | 11.47 |
Support 1 (S1) | 11.29 | 11.30 | 11.38 | 11.33 | 11.08 |
Support 2 (S2) | 11.03 | 11.20 | 11.05 | 11.04 | |
Support 3 (S3) | 10.86 | 11.03 | 11.01 | ||
Support 4 (S4) | 10.90 |